Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $766K | — | — | — | — | $0.00 | $10.0M | $2.81M | $9.78K | $1.03M |
| Revenue growth | — | — | — | — | — | — | — | -71.9% | -99.7% | 10429.4% |
| Operating income | -$631K | -$11.2M | -$16.9M | -$14.3M | -$27.4M | -$39.1M | -$31.4M | -$30.9M | -$23.5M | -$13.6M |
| Operating margin | -82.3% | — | — | — | — | — | -313.9% | -1101.9% | -239692.2% | -1315.5% |
| Net income | -$673K | -$11.5M | -$16.7M | -$14.3M | -$27.4M | -$38.7M | -$30.9M | -$30.2M | -$4.05M | -$13.4M |
| Net margin | -87.8% | — | — | — | — | — | -309.5% | -1074.2% | -41430.9% | -1300.7% |
| EPS (diluted) | -$0.81 | $3.56 | -$1.57 | -$0.97 | -$0.91 | -$0.63 | -$0.37 | -$4.15 | -$0.48 | -$1.20 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$372K | -$2.54M | -$10.3M | -$13.3M | -$25.2M | -$28.8M | -$18.1M | -$38.9M | $5.47M | -$9.89M |
| Capital expenditures | $535K | $0.00 | $11.8K | $0.00 | $17.6K | $14.5K | $63.1K | $629K | $573K | $385K |
| Free cash flow | -$907K | -$2.54M | -$10.3M | -$13.3M | -$25.3M | -$28.8M | -$18.2M | -$39.5M | $4.90M | -$10.3M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $44.6K | $7.56M | $6.81M | $4.78M | $4.67M | $51.7M | $34.7M | $10.5M | $15.7M | $24.7M |
| Total assets | $44.6K | $14.3M | $7.83M | $7.44M | $7.55M | $55.8M | $43.8M | $21.3M | $22.1M | $32.5M |
| Total liabilities | $755K | $967K | $1.10M | $7.00M | $8.70M | $17.1M | $32.7M | $26.3M | $28.1M | $29.6M |
| Shareholders' equity | -$711K | $13.3M | $6.73M | $441K | -$1.15M | $38.8M | $11.1M | -$5.05M | -$6.01M | $2.84M |
| Retained earnings | -$728K | -$12.2M | -$29.0M | -$44.0M | -$71.4M | -$110M | -$141M | -$171M | -$175M | -$189M |
| Shares (wtd avg diluted) | 835K | 3.23M | 11.4M | 19.7M | 30.1M | 61.2M | 84.6M | 7.28M | 8.50M | 11.2M |
Every figure is extracted from Dare Bioscience, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.